

Submitted by:
Neda Nguyen, PharmD
US Medical Affairs
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
Phone: (925) 297-9120
Email: nguyen.neda@gene.com
Date of request: March 16, 2021
NCCN Guidelines Panels: **Small Cell Lung Cancer**

Dear NCCN Guidelines Panel for Small Cell Lung Cancer (SCLC):

On behalf of Genentech, Inc., please find the below request for your review regarding alignment with the updated FDA-approved dosing schedule for the use of Tecentriq® (atezolizumab), per Section 2 Dosage and Administration of the Tecentriq US Prescribing Information.

Request:¹

Please consider updating Tecentriq dosing recommendations to include the additional FDA-approved dosing schedules in the **NCCN Guidelines® for Small Cell Lung Cancer (SCLC), Page SCL-E 1 of 5**

- Additional induction dosing options of Tecentriq 840 mg every 2 weeks, or 1680 mg every 4 weeks
- Additional maintenance dosing options of Tecentriq 840 mg every 2 weeks, or 1680 mg every 4 weeks

Rationale:¹

As of February 17, 2021, the FDA has approved additional dosing regimens for Tecentriq. The dosing schedule has now been standardized and Tecentriq may be administered as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks, across all indications as both monotherapy or in combination with other therapeutic agents.

NCCN Guidelines for SCLC currently include the dosing schedule of 4 cycles every 3 weeks, of Tecentriq in combination with carboplatin and etoposide, followed by maintenance Tecentriq as a Category 1, Preferred option for Primary Therapy for ES-SCLC.

Dosage and Administration for the treatment of SCLC as reflected in the current Tecentriq USPI includes, in addition to Tecentriq 1200 mg every 3 weeks, the flexible dosing options of:

- Tecentriq 840 mg every 2 weeks, or 1680 mg every 4 weeks

FDA Clearance:

- The aforementioned data reflect FDA-approved uses for Tecentriq. Please refer to the product prescribing information for the full FDA-approved indications and safety information, available at: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf.

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,
Neda Nguyen, PharmD

References

1. Tecentriq® [package insert]. Genentech, Inc.; South San Francisco, CA. February 2021.